Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus cCRT Followed by Tislelizumab Versus cCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer

  • Markman, Ben (Primary Chief Investigator (PCI))
  • Spence, Anne (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date30/11/21 → 31/12/26

Keywords

  • Medical oncology
  • Lung cancer
  • Clinical trial